Name (Synonyms) | Correlation | |
---|---|---|
drug1312 | Hydroxychloroquine Sulfate Regular dose Wiki | 0.50 |
drug1311 | Hydroxychloroquine Sulfate Loading Dose Wiki | 0.50 |
drug2195 | Positive Peer Journaling (PPJ) Wiki | 0.35 |
drug2776 | Survey Group Wiki | 0.35 |
drug2872 | Test: Favipiravir 200 mg (LOQULAR) Wiki | 0.35 |
drug2000 | Other drugs Wiki | 0.35 |
drug2398 | Reference: Favipiravir 200 mg (Avigan) Wiki | 0.35 |
drug3520 | zinc Wiki | 0.35 |
drug559 | COVID-19 e-package: Psychological wellbeing for healthcare workers Wiki | 0.35 |
drug3521 | ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. Wiki | 0.35 |
drug1862 | Niclosamide Wiki | 0.25 |
drug1672 | MagPro X100 Stimulator, B70 Fluid-Cooled Coil Wiki | 0.25 |
drug1489 | Ivermectin Wiki | 0.24 |
drug1869 | Nitazoxanide Wiki | 0.22 |
drug922 | Doxycycline Wiki | 0.18 |
drug3468 | standard care Wiki | 0.18 |
drug1087 | Favipiravir Wiki | 0.08 |
drug2161 | Placebo oral tablet Wiki | 0.06 |
drug313 | Azithromycin Wiki | 0.06 |
drug2122 | Placebo Wiki | 0.04 |
drug1284 | Hydroxychloroquine Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D016739 | Behavior, Addictive NIH | 0.53 |
D056660 | Hereditary Autoinflammatory Diseases NIH | 0.35 |
D001528 | Behcet Syndrome NIH | 0.35 |
D010505 | Familial Mediterranean Fever NIH | 0.35 |
D002006 | Brucellosis NIH | 0.35 |
D001714 | Bipolar Disorder NIH | 0.25 |
D019966 | Substance-Related Disorders NIH | 0.24 |
D058070 | Asymptomatic Diseases NIH | 0.20 |
D003866 | Depressive Disorder NIH | 0.08 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D003863 | Depression, NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
D011014 | Pneumonia NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0030858 | Addictive behavior HPO | 0.53 |
HP:0100754 | Mania HPO | 0.25 |
HP:0000716 | Depressivity HPO | 0.08 |
HP:0002090 | Pneumonia HPO | 0.02 |
There are 8 clinical trials
COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.
Description: the estimated number of patients with decreased viral load
Measure: Number of patients with decreased viral load Time: 6 monthsTo create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR negative status Time: 6-7 daysDescription: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Time to onset of fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute).
Measure: Development of Symptoms Time: 7 daysDescription: Drug related adverse events as determined by data safety and monitoring board (DSMB)
Measure: Adverse events Time: 7 daysThe primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.
Description: Symptomatic illness is defined as COVID infection guidelines and confirmed with anti-COVID antibodies that will be done on serum collect at the final visit. Symptoms include fever, chills, muscle pain, cough, shortness of breath, and diarrhea.
Measure: Number of symptomatic illness in at risk healthcare workers Time: Up to 3 monthsDescription: Diagnosis is based on symptoms of COVID-19 and confirmatory anti-COVID antibodies and when available, COVID-19 PCR.
Measure: Number of healthcare workers with symptomatic COVID infections Time: Up to 3 monthsDescription: Severe illness includes worsening of symptoms.
Measure: Number of severe illness in at risk healthcare workers Time: Up to 3 monthsDescription: Confirmation with polymerase chain reaction (PCR) when available.
Measure: Number of sero-conversions in at risk healthcare workers Time: Up to 3 monthsDescription: Adverse events that are NCI-CTCAE Grade 3 or higher will be counted.
Measure: Percentage of patients with adverse events Grade 3 or higher Time: Up to 3 monthsDescription: GI intolerance to chloroquine will be documented and recorded.
Measure: Percentage of patients with GI intolerance Time: Up to 3 monthsTo treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR result Time: 6th and 7th dayDescription: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Death
Measure: Mortality Time: 30 daysAzithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Description: the number of patients with virological cure
Measure: Number of patients with virological cure Time: 6 monthsEfficacy of Ivermectin and Doxycycline in COVID-19 treatment
Description: The number of patients with improvement or mortality
Measure: The number of patients with improvement or mortality Time: 1 monthFacing the challenge of finding an efficient treatment for COVID-19, the viral pneumonia caused by the Coronavirus SARS-Cov-2, this study intended to test if Chloroquine or Hydroxychloroquine, two drugs with strong in-vitro antiviral role proven by numerous studies and with a well defined safety profile established, for efficacy in treating COVID-19 and improving an ordinal primary outcome composed by a 9-levels scale, which was recomended by the World Health Organization.
Description: 9-levels scale recomended by WHO for studies related to treating COVID-19
Measure: World Health Organization (WHO) 9-levels scale (from 0-8) Time: Day14Description: 9-levels scale recomended by WHO for studies related to treating COVID-19, with lower scores meaning better outcomes (0 means at home with no symptoms and
Measure: WHO 9-levels scale (from 0-8) Time: Day 28Description: 28day mortality
Measure: Mortality Time: Day 28Description: Days without need of Mechanical Ventilation
Measure: Ventilation free days Time: Day 28.Description: Trigger system aligned to the scale of clinical risk. Minimum score is 0 (better outcome) and maximum score is 20 (worse outcome). The higher the score, the higher the risk.
Measure: National Early Warning Score (NEWS) Time: Day 7Description: Trigger system aligned to the scale of clinical risk. Minimum score is 0 (better outcome) and maximum score is 20 (worse outcome). The higher the score, the higher the risk.
Measure: National Early Warning Score (NEWS) Time: Day 14Description: Trigger system aligned to the scale of clinical risk. Minimum score is 0 (better outcome) and maximum score is 20 (worse outcome). The higher the score, the higher the risk.
Measure: National Early Warning Score (NEWS) Time: Day 28we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19.
Description: The number of patients with improvement or mortality.
Measure: Number of patients with improvement or mortality Time: 2 weeks